The most recent trading session ended with Gilead Sciences (GILD) standing at $93.85, reflecting a -1.57% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain ...

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target remains the same with $95.00. Tyler Van Buren’s ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $115.00. The company’s shares closed yesterday at $93.85.

TEANECK, N.J. - Cognizant Technology Solutions (NASDAQ:CTSH) Corporation (NASDAQ: CTSH) has announced the expansion of its partnership with biopharmaceutical company Gilead Sciences (NASDAQ ...

Gilead Sciences GILD has outperformed the market over the past 20 years by 4.74% on an annualized basis producing an average annual return of 13.14%. Currently, Gilead Sciences has a market ...

TEANECK (dpa-AFX) - Cognizant (CTSH) Thursday announced that it has expanded its long-standing collaboration with Gilead Sciences (GILD) to enhance cost efficiency and productivity. The ...

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. Galapagos NV plans to split into two entities ...

"The View" co-host Sara Haines suggested Monday that she and her co-hosts are out-of-touch with a large portion of the American electorate on immigration. Over the first weekend of President ...